Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin

Neel Mehta, Iwona Bucior, Shay Bujanover, Rajiv Shah, Amitabh Gulati, Neel Mehta, Iwona Bucior, Shay Bujanover, Rajiv Shah, Amitabh Gulati

Abstract

Background: Postherpetic neuralgia (PHN) interferes with patients' quality of life, and disturbed sleep is a prevalent complaint. Pain-associated sleep interference in turn enhances pain and/or reduces pain tolerance. Therefore, reducing sleep interference by pain, in addition to pain control, may improve patient care. To address this notion, we characterized relationships among changes in pain intensity, sleep interference, and overall impression of improvement in PHN patients treated with gastroretentive gabapentin (G-GR).

Methods: Patients with PHN (n = 556) received G-GR 1,800 mg once-daily in two phase 3 and one phase 4 study. Visual Analog Scale (VAS) and Brief Pain Inventory (BPI) were completed at baseline and the end of study. Patients' Global Impression of Change (PGIC) was completed at the end of study. Regression analyses examined relationships between VAS, BPI sleep interference by pain, and PGIC.

Results: At the end of treatment, 53.7 and 63.2 % of patients reported a ≥ 30 % reduction in VAS and BPI pain-associated sleep interference (BPISI) respectively; 46.3 % reported feeling "Much" or "Very Much" improved on the PGIC. There were positive correlations between the percent reductions in VAS and BPISI; both correlated with PGIC improvements. Percent changes in VAS and BPISI were significant (p < 0.0001 and p = 0.0082, respectively), and were independent predictors of feeling "Much" or "Very Much" improved on the PGIC.

Conclusions: Reductions in pain intensity and in BPISI were correlated, and both also correlated with overall impression of improvement for patients with PHN treated with G-GR. Both pain relief and improvement BPISI independently predicted improvement in PGIC. For optimal patient care, clinicians should consider reducing the impact of pain on quality of sleep as well as overall pain reduction.

Trial registration: ClinicalTrials.gov numbers, NCT00335933 , NCT00636636 , NCT01426230.

Keywords: Gabapentin; Gastroretentive; Neuropathic pain; Postherpetic neuralgia; Quality of life; Sleep.

Figures

Fig. 1
Fig. 1
Proportion of patients who reported ≥30 % reductions in the VAS or BPI Sleep Interference by Pain scores, or who reported feeling “Much” or “Very Much” improved at the end of G-GR treatment
Fig. 2
Fig. 2
Percent reduction from baseline in the BPISI score by categories of percent reduction from baseline in the VAS score
Fig. 3
Fig. 3
Percent reduction from baseline in the VAS (a) and BPISI (b) scores by categories of improvement on the PGIC
Fig. 4
Fig. 4
Influence of the VAS and BPI Sleep Interference by Pain scores on the probability to be “Much” or “Very Much” improved on the PGIC. Probabilities to be “Much” or “Very Much” improved on the PGIC were determined by multiple logistic regression analyses for percent changes from baseline in the VAS score (a) and BPI Sleep Interference by Pain score (b), and for baseline VAS (c) and BPI Sleep Interference by Pain (d) scores

References

    1. Gharibo C, Kim C. Neuropathic pain of postherpetic neuralgia. Pain Med News. 2011;9:84–92.
    1. Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract. 2011;11:397–402. doi: 10.1111/j.1533-2500.2010.00432.x.
    1. Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012;20:441–51. doi: 10.1007/s10389-011-0481-8.
    1. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178–82. doi: 10.1212/01.wnl.0000259085.61898.9e.
    1. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–6. doi: 10.1503/cmaj.091711.
    1. Roehrs T, Roth T. Sleep and pain: interaction of two vital functions. Semin Neurol. 2005;25:106–16. doi: 10.1055/s-2005-867079.
    1. Odrcich M, Bailey JM, Cahill CM, Gilron I. Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy. Pain. 2006;120:207–12. doi: 10.1016/j.pain.2005.10.007.
    1. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and pain perception. Sleep Med Rev. 2006;10:357–69. doi: 10.1016/j.smrv.2005.08.001.
    1. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374–85. doi: 10.1016/j.jpainsymman.2005.04.009.
    1. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23:15–22. doi: 10.1097/01.ajp.0000210945.27052.b3.
    1. Roehrs TA, Harris E, Randall S, Roth T. Pain sensitivity and recovery from mild chronic sleep loss. Sleep. 2012;35:1667–72.
    1. Chhangani BS, Roehrs TA, Harris EJ, Hyde M, Drake C, Hudgel DW, et al. Pain sensitivity in sleepy pain-free normals. Sleep. 2009;32:1011–7.
    1. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8:119–32. doi: 10.1016/S1087-0792(03)00044-3.
    1. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35:612–23. doi: 10.1016/j.clinthera.2013.03.008.
    1. Rauck RL, Irving GA, Wallace MS, Vanhove GF, Sweeney M. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Pain Symptom Manage. 2013;46:219–28. doi: 10.1016/j.jpainsymman.2012.07.011.
    1. Gupta A, Li S. Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over. Drugs Aging. 2013;30:999–1008. doi: 10.1007/s40266-013-0126-4.
    1. Backonja MM, Canafax DM, Cundy KC. Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. Pain Med. 2011;12:1098–108. doi: 10.1111/j.1526-4637.2011.01139.x.
    1. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–42. doi: 10.1001/jama.280.21.1837.
    1. Rice ASC, Maton S, Group PNS. Gabapentin in posterpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215–24. doi: 10.1016/S0304-3959(01)00407-9.
    1. Kantor D, Panchal S, Patel V, Bucior I, Rauck R. Treatment of postherpetic neuralgia with gastroretentive gabapentin: interaction of patient demographics, disease characteristics, and efficacy outcomes. J Pain. 2015;16:1300–11. doi: 10.1016/j.jpain.2015.08.011.
    1. Wallace MS, Irving G, Cowles VE. Gabapentin extended-release tablets for the treatment of patients with postherpetic neuralgia: a randomized, double-blind, placebo-controlled, multicentre study. Clin Drug Investig. 2010;30:765–76. doi: 10.2165/11539520-000000000-00000.
    1. Sang CN, Sathyanarayana R, Sweeney M, Investigators DMS. Gastroretentive gabapentin (G-GR) formulation reduces intensity of pain associated with postherpetic neuralgia (PHN) Clin J Pain. 2013;29:281–8. doi: 10.1097/AJP.0b013e318258993e.
    1. Markley HG, Dunteman ED, Kareht S, Sweeney M. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN) Clin J Pain. 2015;31:58–65. doi: 10.1097/AJP.0000000000000082.
    1. Farrar JD, Young JPJ, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58. doi: 10.1016/S0304-3959(01)00349-9.
    1. Ostelo RW, Deyo RA, Stratford P, Waddell G, Croft P, Von Korff M, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine. 2008;33:90–4. doi: 10.1097/BRS.0b013e31815e3a10.
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–21. doi: 10.1016/j.jpain.2007.09.005.
    1. Belgrade MJ. Following the clues to neuropathic pain. Distribution and other leads reveal the cause and the treatment approach. Postgrad Med. 1999;106:127–32. doi: 10.3810/pgm.1999.11.770.
    1. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain. 2009;146:238–44. doi: 10.1016/j.pain.2009.08.019.
    1. Perez-Lloret S, Rojas GM, Menoni MC, Ruiz G, Velasquez C, Rodriguez H, et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol. 2012;35:21–4. doi: 10.1097/WNF.0b013e31823df2dc.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel